Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee.
Related news for (PASG)
- Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights